nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—Abortion spontaneous—Fluorouracil—stomach cancer	0.0647	0.0797	CcSEcCtD
Gonadorelin—Embolism—Floxuridine—stomach cancer	0.0418	0.0515	CcSEcCtD
Gonadorelin—Developmental delay—Fluorouracil—stomach cancer	0.023	0.0284	CcSEcCtD
Gonadorelin—Congenital anomaly—Fluorouracil—stomach cancer	0.023	0.0284	CcSEcCtD
Gonadorelin—Injection site reaction—Mitomycin—stomach cancer	0.0209	0.0258	CcSEcCtD
Gonadorelin—Congenital anomaly—Capecitabine—stomach cancer	0.0161	0.0198	CcSEcCtD
Gonadorelin—Developmental delay—Capecitabine—stomach cancer	0.0161	0.0198	CcSEcCtD
Gonadorelin—Embolism—Irinotecan—stomach cancer	0.0142	0.0175	CcSEcCtD
Gonadorelin—Thromboembolism—Epirubicin—stomach cancer	0.0134	0.0165	CcSEcCtD
Gonadorelin—Thromboembolism—Doxorubicin—stomach cancer	0.0124	0.0153	CcSEcCtD
Gonadorelin—Erythema—Floxuridine—stomach cancer	0.0117	0.0145	CcSEcCtD
Gonadorelin—GNRHR—GPCRs, Other—HRH4—stomach cancer	0.0101	0.0533	CbGpPWpGaD
Gonadorelin—Embolism—Docetaxel—stomach cancer	0.00984	0.0121	CcSEcCtD
Gonadorelin—Haematoma—Capecitabine—stomach cancer	0.00973	0.012	CcSEcCtD
Gonadorelin—Anaphylactic shock—Floxuridine—stomach cancer	0.00956	0.0118	CcSEcCtD
Gonadorelin—Embolism—Capecitabine—stomach cancer	0.00953	0.0117	CcSEcCtD
Gonadorelin—Nervous system disorder—Floxuridine—stomach cancer	0.00938	0.0116	CcSEcCtD
Gonadorelin—Redness—Docetaxel—stomach cancer	0.00936	0.0115	CcSEcCtD
Gonadorelin—Erythema—Mitomycin—stomach cancer	0.0092	0.0113	CcSEcCtD
Gonadorelin—Embolism venous—Epirubicin—stomach cancer	0.00844	0.0104	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—KISS1R—stomach cancer	0.00783	0.0414	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Floxuridine—stomach cancer	0.00782	0.00964	CcSEcCtD
Gonadorelin—Embolism venous—Doxorubicin—stomach cancer	0.00781	0.00963	CcSEcCtD
Gonadorelin—Abdominal pain—Floxuridine—stomach cancer	0.00756	0.00932	CcSEcCtD
Gonadorelin—Shock—Mitomycin—stomach cancer	0.00738	0.00911	CcSEcCtD
Gonadorelin—Swelling—Fluorouracil—stomach cancer	0.0072	0.00888	CcSEcCtD
Gonadorelin—Embolism—Methotrexate—stomach cancer	0.00709	0.00874	CcSEcCtD
Gonadorelin—Hypersensitivity—Floxuridine—stomach cancer	0.00705	0.00869	CcSEcCtD
Gonadorelin—Contusion—Capecitabine—stomach cancer	0.00701	0.00864	CcSEcCtD
Gonadorelin—Pelvic pain—Epirubicin—stomach cancer	0.007	0.00863	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1R—stomach cancer	0.007	0.037	CbGpPWpGaD
Gonadorelin—GNRHR—Peptide GPCRs—AGTR2—stomach cancer	0.0069	0.0365	CbGpPWpGaD
Gonadorelin—Asthenia—Floxuridine—stomach cancer	0.00686	0.00846	CcSEcCtD
Gonadorelin—Embolism—Epirubicin—stomach cancer	0.00664	0.00818	CcSEcCtD
Gonadorelin—Diarrhoea—Floxuridine—stomach cancer	0.00654	0.00807	CcSEcCtD
Gonadorelin—Pelvic pain—Doxorubicin—stomach cancer	0.00648	0.00799	CcSEcCtD
Gonadorelin—Fatigue—Mitomycin—stomach cancer	0.00647	0.00798	CcSEcCtD
Gonadorelin—Pain—Mitomycin—stomach cancer	0.00642	0.00791	CcSEcCtD
Gonadorelin—Redness—Epirubicin—stomach cancer	0.00631	0.00778	CcSEcCtD
Gonadorelin—Injection site reaction—Docetaxel—stomach cancer	0.00628	0.00774	CcSEcCtD
Gonadorelin—Embolism—Doxorubicin—stomach cancer	0.00614	0.00757	CcSEcCtD
Gonadorelin—Vomiting—Floxuridine—stomach cancer	0.00608	0.0075	CcSEcCtD
Gonadorelin—Injection site reaction—Capecitabine—stomach cancer	0.00608	0.0075	CcSEcCtD
Gonadorelin—Headache—Floxuridine—stomach cancer	0.00599	0.00739	CcSEcCtD
Gonadorelin—Redness—Doxorubicin—stomach cancer	0.00584	0.0072	CcSEcCtD
Gonadorelin—GNRHR—GPCRs, Other—F2R—stomach cancer	0.00578	0.0306	CbGpPWpGaD
Gonadorelin—Nausea—Floxuridine—stomach cancer	0.00568	0.00701	CcSEcCtD
Gonadorelin—Asthenia—Mitomycin—stomach cancer	0.00539	0.00664	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Irinotecan—stomach cancer	0.00533	0.00657	CcSEcCtD
Gonadorelin—Swelling—Docetaxel—stomach cancer	0.0052	0.00641	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.00518	0.0274	CbGpPWpGaD
Gonadorelin—Diarrhoea—Mitomycin—stomach cancer	0.00514	0.00633	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Fluorouracil—stomach cancer	0.0051	0.00629	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—KISS1—stomach cancer	0.00504	0.0267	CbGpPWpGaD
Gonadorelin—Swelling—Capecitabine—stomach cancer	0.00503	0.0062	CcSEcCtD
Gonadorelin—Breast pain—Epirubicin—stomach cancer	0.00488	0.00602	CcSEcCtD
Gonadorelin—Vomiting—Mitomycin—stomach cancer	0.00477	0.00588	CcSEcCtD
Gonadorelin—Headache—Mitomycin—stomach cancer	0.0047	0.0058	CcSEcCtD
Gonadorelin—Breast pain—Doxorubicin—stomach cancer	0.00452	0.00557	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—stomach cancer	0.00451	0.0239	CbGpPWpGaD
Gonadorelin—Nausea—Mitomycin—stomach cancer	0.00446	0.0055	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—RGS2—stomach cancer	0.00434	0.0229	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—GAST—stomach cancer	0.00434	0.0229	CbGpPWpGaD
Gonadorelin—GNRHR—GPCRs, Other—ADRB2—stomach cancer	0.00427	0.0226	CbGpPWpGaD
Gonadorelin—Injection site reaction—Epirubicin—stomach cancer	0.00423	0.00522	CcSEcCtD
Gonadorelin—Angiopathy—Irinotecan—stomach cancer	0.00416	0.00513	CcSEcCtD
Gonadorelin—Immune system disorder—Irinotecan—stomach cancer	0.00414	0.00511	CcSEcCtD
Gonadorelin—Breast disorder—Docetaxel—stomach cancer	0.00414	0.00511	CcSEcCtD
Gonadorelin—Breast disorder—Capecitabine—stomach cancer	0.00401	0.00495	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—KISS1R—stomach cancer	0.00395	0.0209	CbGpPWpGaD
Gonadorelin—Flatulence—Irinotecan—stomach cancer	0.00394	0.00485	CcSEcCtD
Gonadorelin—Injection site reaction—Doxorubicin—stomach cancer	0.00392	0.00483	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RGS2—stomach cancer	0.00388	0.0205	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—stomach cancer	0.00388	0.0205	CbGpPWpGaD
Gonadorelin—Erythema—Fluorouracil—stomach cancer	0.00383	0.00472	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.00375	0.0198	CbGpPWpGaD
Gonadorelin—Abdominal discomfort—Capecitabine—stomach cancer	0.00368	0.00453	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Capecitabine—stomach cancer	0.00357	0.0044	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.00334	0.0177	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Irinotecan—stomach cancer	0.00326	0.00402	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—F2R—stomach cancer	0.00325	0.0172	CbGpPWpGaD
Gonadorelin—Shock—Irinotecan—stomach cancer	0.00321	0.00395	CcSEcCtD
Gonadorelin—Nervous system disorder—Irinotecan—stomach cancer	0.0032	0.00394	CcSEcCtD
Gonadorelin—Anaphylactic shock—Fluorouracil—stomach cancer	0.00312	0.00385	CcSEcCtD
Gonadorelin—Nervous system disorder—Fluorouracil—stomach cancer	0.00306	0.00378	CcSEcCtD
Gonadorelin—GNRHR—G alpha (q) signalling events—ANXA1—stomach cancer	0.00306	0.0162	CbGpPWpGaD
Gonadorelin—Breast disorder—Methotrexate—stomach cancer	0.00299	0.00368	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—stomach cancer	0.00291	0.0154	CbGpPWpGaD
Gonadorelin—Angiopathy—Docetaxel—stomach cancer	0.00288	0.00355	CcSEcCtD
Gonadorelin—Immune system disorder—Docetaxel—stomach cancer	0.00286	0.00353	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—HRH4—stomach cancer	0.00285	0.0151	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Irinotecan—stomach cancer	0.00281	0.00347	CcSEcCtD
Gonadorelin—Fatigue—Irinotecan—stomach cancer	0.00281	0.00347	CcSEcCtD
Gonadorelin—Breast disorder—Epirubicin—stomach cancer	0.00279	0.00345	CcSEcCtD
Gonadorelin—Pain—Irinotecan—stomach cancer	0.00279	0.00344	CcSEcCtD
Gonadorelin—Constipation—Irinotecan—stomach cancer	0.00279	0.00344	CcSEcCtD
Gonadorelin—Angiopathy—Capecitabine—stomach cancer	0.00279	0.00344	CcSEcCtD
Gonadorelin—Immune system disorder—Capecitabine—stomach cancer	0.00277	0.00342	CcSEcCtD
Gonadorelin—Erythema—Docetaxel—stomach cancer	0.00276	0.0034	CcSEcCtD
Gonadorelin—Abdominal discomfort—Methotrexate—stomach cancer	0.00274	0.00338	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—stomach cancer	0.00273	0.0145	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.0027	0.00332	CcSEcCtD
Gonadorelin—Erythema—Capecitabine—stomach cancer	0.00267	0.0033	CcSEcCtD
Gonadorelin—Pain—Fluorouracil—stomach cancer	0.00267	0.00329	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Irinotecan—stomach cancer	0.00267	0.00329	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Methotrexate—stomach cancer	0.00265	0.00327	CcSEcCtD
Gonadorelin—Flatulence—Capecitabine—stomach cancer	0.00263	0.00325	CcSEcCtD
Gonadorelin—Breast disorder—Doxorubicin—stomach cancer	0.00259	0.00319	CcSEcCtD
Gonadorelin—Abdominal pain—Irinotecan—stomach cancer	0.00258	0.00318	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—KISS1—stomach cancer	0.00254	0.0135	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Epirubicin—stomach cancer	0.00248	0.00306	CcSEcCtD
Gonadorelin—Hypersensitivity—Irinotecan—stomach cancer	0.0024	0.00296	CcSEcCtD
Gonadorelin—Asthenia—Irinotecan—stomach cancer	0.00234	0.00288	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—stomach cancer	0.00232	0.0123	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Fluorouracil—stomach cancer	0.0023	0.00284	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Doxorubicin—stomach cancer	0.0023	0.00283	CcSEcCtD
Gonadorelin—Anaphylactic shock—Docetaxel—stomach cancer	0.00225	0.00278	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—KISS1R—stomach cancer	0.00223	0.0118	CbGpPWpGaD
Gonadorelin—Diarrhoea—Irinotecan—stomach cancer	0.00223	0.00275	CcSEcCtD
Gonadorelin—Shock—Docetaxel—stomach cancer	0.00222	0.00273	CcSEcCtD
Gonadorelin—Nervous system disorder—Docetaxel—stomach cancer	0.00221	0.00272	CcSEcCtD
Gonadorelin—Pruritus—Fluorouracil—stomach cancer	0.00221	0.00272	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.00218	0.0115	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.00215	0.0114	CbGpPWpGaD
Gonadorelin—Shock—Capecitabine—stomach cancer	0.00215	0.00265	CcSEcCtD
Gonadorelin—Nervous system disorder—Capecitabine—stomach cancer	0.00214	0.00264	CcSEcCtD
Gonadorelin—Diarrhoea—Fluorouracil—stomach cancer	0.00214	0.00263	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.0021	0.0111	CbGpPWpGaD
Gonadorelin—Angiopathy—Methotrexate—stomach cancer	0.00207	0.00256	CcSEcCtD
Gonadorelin—Vomiting—Irinotecan—stomach cancer	0.00207	0.00256	CcSEcCtD
Gonadorelin—Immune system disorder—Methotrexate—stomach cancer	0.00206	0.00255	CcSEcCtD
Gonadorelin—Headache—Irinotecan—stomach cancer	0.00204	0.00252	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—KISS1R—stomach cancer	0.00203	0.0107	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.00202	0.0107	CbGpPWpGaD
Gonadorelin—Erythema—Methotrexate—stomach cancer	0.00199	0.00245	CcSEcCtD
Gonadorelin—Vomiting—Fluorouracil—stomach cancer	0.00198	0.00245	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.00196	0.0104	CbGpPWpGaD
Gonadorelin—Headache—Fluorouracil—stomach cancer	0.00196	0.00241	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Docetaxel—stomach cancer	0.00195	0.0024	CcSEcCtD
Gonadorelin—Fatigue—Docetaxel—stomach cancer	0.00194	0.0024	CcSEcCtD
Gonadorelin—Angiopathy—Epirubicin—stomach cancer	0.00194	0.00239	CcSEcCtD
Gonadorelin—Nausea—Irinotecan—stomach cancer	0.00194	0.00239	CcSEcCtD
Gonadorelin—Immune system disorder—Epirubicin—stomach cancer	0.00193	0.00238	CcSEcCtD
Gonadorelin—Pain—Docetaxel—stomach cancer	0.00193	0.00238	CcSEcCtD
Gonadorelin—Constipation—Docetaxel—stomach cancer	0.00193	0.00238	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Capecitabine—stomach cancer	0.00188	0.00232	CcSEcCtD
Gonadorelin—Fatigue—Capecitabine—stomach cancer	0.00188	0.00232	CcSEcCtD
Gonadorelin—Pain—Capecitabine—stomach cancer	0.00187	0.0023	CcSEcCtD
Gonadorelin—Constipation—Capecitabine—stomach cancer	0.00187	0.0023	CcSEcCtD
Gonadorelin—Erythema—Epirubicin—stomach cancer	0.00186	0.0023	CcSEcCtD
Gonadorelin—Nausea—Fluorouracil—stomach cancer	0.00185	0.00229	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Docetaxel—stomach cancer	0.00184	0.00227	CcSEcCtD
Gonadorelin—Flatulence—Epirubicin—stomach cancer	0.00184	0.00226	CcSEcCtD
Gonadorelin—Angiopathy—Doxorubicin—stomach cancer	0.0018	0.00221	CcSEcCtD
Gonadorelin—Immune system disorder—Doxorubicin—stomach cancer	0.00179	0.0022	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Capecitabine—stomach cancer	0.00178	0.0022	CcSEcCtD
Gonadorelin—Abdominal pain—Docetaxel—stomach cancer	0.00178	0.0022	CcSEcCtD
Gonadorelin—Abdominal pain—Capecitabine—stomach cancer	0.00172	0.00213	CcSEcCtD
Gonadorelin—Erythema—Doxorubicin—stomach cancer	0.00172	0.00212	CcSEcCtD
Gonadorelin—Flatulence—Doxorubicin—stomach cancer	0.0017	0.00209	CcSEcCtD
Gonadorelin—Hypersensitivity—Docetaxel—stomach cancer	0.00166	0.00205	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—AGTR2—stomach cancer	0.00166	0.00877	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—F2R—stomach cancer	0.00164	0.00867	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Methotrexate—stomach cancer	0.00162	0.002	CcSEcCtD
Gonadorelin—Asthenia—Docetaxel—stomach cancer	0.00162	0.00199	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—HRH4—stomach cancer	0.00161	0.00853	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Capecitabine—stomach cancer	0.00161	0.00198	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—HTR1A—stomach cancer	0.0016	0.00844	CbGpPWpGaD
Gonadorelin—Pruritus—Docetaxel—stomach cancer	0.00159	0.00197	CcSEcCtD
Gonadorelin—Nervous system disorder—Methotrexate—stomach cancer	0.00159	0.00196	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.00159	0.0084	CbGpPWpGaD
Gonadorelin—Asthenia—Capecitabine—stomach cancer	0.00157	0.00193	CcSEcCtD
Gonadorelin—Pruritus—Capecitabine—stomach cancer	0.00154	0.0019	CcSEcCtD
Gonadorelin—Diarrhoea—Docetaxel—stomach cancer	0.00154	0.0019	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ANXA1—stomach cancer	0.00154	0.00815	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Epirubicin—stomach cancer	0.00152	0.00187	CcSEcCtD
Gonadorelin—Shock—Epirubicin—stomach cancer	0.0015	0.00184	CcSEcCtD
Gonadorelin—Diarrhoea—Capecitabine—stomach cancer	0.00149	0.00184	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ADRB1—stomach cancer	0.00149	0.0079	CbGpPWpGaD
Gonadorelin—Nervous system disorder—Epirubicin—stomach cancer	0.00149	0.00184	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—HRH4—stomach cancer	0.00146	0.00775	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—stomach cancer	0.00146	0.00775	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—KISS1—stomach cancer	0.00144	0.00761	CbGpPWpGaD
Gonadorelin—Vomiting—Docetaxel—stomach cancer	0.00143	0.00177	CcSEcCtD
Gonadorelin—Headache—Docetaxel—stomach cancer	0.00141	0.00174	CcSEcCtD
Gonadorelin—Anaphylactic shock—Doxorubicin—stomach cancer	0.00141	0.00173	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Methotrexate—stomach cancer	0.0014	0.00173	CcSEcCtD
Gonadorelin—Fatigue—Methotrexate—stomach cancer	0.0014	0.00173	CcSEcCtD
Gonadorelin—Pain—Methotrexate—stomach cancer	0.00139	0.00171	CcSEcCtD
Gonadorelin—Vomiting—Capecitabine—stomach cancer	0.00139	0.00171	CcSEcCtD
Gonadorelin—Shock—Doxorubicin—stomach cancer	0.00138	0.00171	CcSEcCtD
Gonadorelin—Nervous system disorder—Doxorubicin—stomach cancer	0.00138	0.0017	CcSEcCtD
Gonadorelin—Headache—Capecitabine—stomach cancer	0.00137	0.00169	CcSEcCtD
Gonadorelin—Nausea—Docetaxel—stomach cancer	0.00134	0.00165	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Methotrexate—stomach cancer	0.00133	0.00164	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Epirubicin—stomach cancer	0.00131	0.00162	CcSEcCtD
Gonadorelin—Fatigue—Epirubicin—stomach cancer	0.00131	0.00162	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—stomach cancer	0.00131	0.00691	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—KISS1—stomach cancer	0.00131	0.00691	CbGpPWpGaD
Gonadorelin—Pain—Epirubicin—stomach cancer	0.0013	0.0016	CcSEcCtD
Gonadorelin—Constipation—Epirubicin—stomach cancer	0.0013	0.0016	CcSEcCtD
Gonadorelin—Nausea—Capecitabine—stomach cancer	0.0013	0.0016	CcSEcCtD
Gonadorelin—Abdominal pain—Methotrexate—stomach cancer	0.00128	0.00158	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Epirubicin—stomach cancer	0.00124	0.00153	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—RGS2—stomach cancer	0.00124	0.00654	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GAST—stomach cancer	0.00124	0.00654	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.00121	0.0015	CcSEcCtD
Gonadorelin—Fatigue—Doxorubicin—stomach cancer	0.00121	0.00149	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—ADRB2—stomach cancer	0.00121	0.0064	CbGpPWpGaD
Gonadorelin—Constipation—Doxorubicin—stomach cancer	0.0012	0.00148	CcSEcCtD
Gonadorelin—Pain—Doxorubicin—stomach cancer	0.0012	0.00148	CcSEcCtD
Gonadorelin—Abdominal pain—Epirubicin—stomach cancer	0.0012	0.00148	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GLI3—stomach cancer	0.0012	0.00633	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KISS1R—stomach cancer	0.0012	0.00633	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Methotrexate—stomach cancer	0.0012	0.00148	CcSEcCtD
Gonadorelin—Asthenia—Methotrexate—stomach cancer	0.00117	0.00144	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Doxorubicin—stomach cancer	0.00115	0.00142	CcSEcCtD
Gonadorelin—Pruritus—Methotrexate—stomach cancer	0.00115	0.00142	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—RBP1—stomach cancer	0.00114	0.00604	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GAST—stomach cancer	0.00112	0.00594	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—RGS2—stomach cancer	0.00112	0.00594	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Epirubicin—stomach cancer	0.00112	0.00138	CcSEcCtD
Gonadorelin—Abdominal pain—Doxorubicin—stomach cancer	0.00111	0.00137	CcSEcCtD
Gonadorelin—Diarrhoea—Methotrexate—stomach cancer	0.00111	0.00137	CcSEcCtD
Gonadorelin—Asthenia—Epirubicin—stomach cancer	0.00109	0.00134	CcSEcCtD
Gonadorelin—Pruritus—Epirubicin—stomach cancer	0.00108	0.00133	CcSEcCtD
Gonadorelin—Diarrhoea—Epirubicin—stomach cancer	0.00104	0.00128	CcSEcCtD
Gonadorelin—Hypersensitivity—Doxorubicin—stomach cancer	0.00104	0.00128	CcSEcCtD
Gonadorelin—Vomiting—Methotrexate—stomach cancer	0.00103	0.00127	CcSEcCtD
Gonadorelin—Headache—Methotrexate—stomach cancer	0.00102	0.00125	CcSEcCtD
Gonadorelin—Asthenia—Doxorubicin—stomach cancer	0.00101	0.00124	CcSEcCtD
Gonadorelin—Pruritus—Doxorubicin—stomach cancer	0.000995	0.00123	CcSEcCtD
Gonadorelin—Vomiting—Epirubicin—stomach cancer	0.000966	0.00119	CcSEcCtD
Gonadorelin—Nausea—Methotrexate—stomach cancer	0.000965	0.00119	CcSEcCtD
Gonadorelin—Diarrhoea—Doxorubicin—stomach cancer	0.000962	0.00119	CcSEcCtD
Gonadorelin—Headache—Epirubicin—stomach cancer	0.000952	0.00117	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—AGTR2—stomach cancer	0.000937	0.00496	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—WWOX—stomach cancer	0.000931	0.00492	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—F2R—stomach cancer	0.000926	0.0049	CbGpPWpGaD
Gonadorelin—Nausea—Epirubicin—stomach cancer	0.000903	0.00111	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—HTR1A—stomach cancer	0.000902	0.00477	CbGpPWpGaD
Gonadorelin—Vomiting—Doxorubicin—stomach cancer	0.000894	0.0011	CcSEcCtD
Gonadorelin—Headache—Doxorubicin—stomach cancer	0.000881	0.00109	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—ANXA1—stomach cancer	0.000871	0.00461	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HRH4—stomach cancer	0.000865	0.00458	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—WIF1—stomach cancer	0.000865	0.00458	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AGTR2—stomach cancer	0.000851	0.0045	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ADRB1—stomach cancer	0.000843	0.00446	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—F2R—stomach cancer	0.000841	0.00445	CbGpPWpGaD
Gonadorelin—Nausea—Doxorubicin—stomach cancer	0.000835	0.00103	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—HTR1A—stomach cancer	0.000819	0.00433	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PRKAB1—stomach cancer	0.000798	0.00422	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—stomach cancer	0.000796	0.00421	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ANXA1—stomach cancer	0.000791	0.00418	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KISS1—stomach cancer	0.000771	0.00408	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RNF43—stomach cancer	0.000771	0.00408	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	0.000767	0.00406	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADRB1—stomach cancer	0.000766	0.00405	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—stomach cancer	0.000757	0.00401	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—stomach cancer	0.000757	0.00401	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—PIK3CA—stomach cancer	0.000735	0.00389	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—stomach cancer	0.000715	0.00378	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FST—stomach cancer	0.000687	0.00364	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ADRB2—stomach cancer	0.000683	0.00362	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—HBEGF—stomach cancer	0.000672	0.00356	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RGS2—stomach cancer	0.000663	0.00351	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GAST—stomach cancer	0.000663	0.00351	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—stomach cancer	0.000657	0.00348	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGG—stomach cancer	0.000629	0.00333	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ADRB2—stomach cancer	0.000621	0.00328	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PPP2R1A—stomach cancer	0.000608	0.00322	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	0.000608	0.00322	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PRKAA1—stomach cancer	0.000605	0.0032	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RBP4—stomach cancer	0.000584	0.00309	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL8—stomach cancer	0.000584	0.00309	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	0.000582	0.00308	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HSPB1—stomach cancer	0.000503	0.00266	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AGTR2—stomach cancer	0.000503	0.00266	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—F2R—stomach cancer	0.000497	0.00263	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—BMP2—stomach cancer	0.000497	0.00263	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKR1C3—stomach cancer	0.000489	0.00259	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HTR1A—stomach cancer	0.000484	0.00256	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PRKCB—stomach cancer	0.000468	0.00248	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ANXA1—stomach cancer	0.000467	0.00247	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADRB1—stomach cancer	0.000452	0.00239	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RPS6—stomach cancer	0.000432	0.00229	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PRKCB—stomach cancer	0.000425	0.00225	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6ST—stomach cancer	0.000424	0.00224	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HBEGF—stomach cancer	0.000397	0.0021	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6R—stomach cancer	0.000378	0.002	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—RHOA—stomach cancer	0.000376	0.00199	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADRB2—stomach cancer	0.000367	0.00194	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PPP2R1A—stomach cancer	0.000359	0.0019	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—RHOA—stomach cancer	0.000341	0.00181	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SMAD4—stomach cancer	0.000334	0.00176	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL8—stomach cancer	0.00033	0.00175	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FYN—stomach cancer	0.000317	0.00168	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL8—stomach cancer	0.0003	0.00159	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGFR2—stomach cancer	0.000297	0.00157	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IRS2—stomach cancer	0.000272	0.00144	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CAV1—stomach cancer	0.000264	0.0014	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APOA1—stomach cancer	0.000263	0.00139	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PRKCB—stomach cancer	0.000251	0.00133	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6ST—stomach cancer	0.00025	0.00132	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APC—stomach cancer	0.00024	0.00127	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MAPK3—stomach cancer	0.00023	0.00122	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6R—stomach cancer	0.000223	0.00118	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MAPK1—stomach cancer	0.000219	0.00116	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EGFR—stomach cancer	0.000219	0.00116	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CA—stomach cancer	0.000209	0.00111	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SERPINE1—stomach cancer	0.000209	0.00111	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—KRAS—stomach cancer	0.000207	0.00109	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RHOA—stomach cancer	0.000202	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOS3—stomach cancer	0.0002	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CA—stomach cancer	0.00019	0.00101	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB2—stomach cancer	0.000187	0.000988	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL8—stomach cancer	0.000177	0.000937	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—HRAS—stomach cancer	0.000176	0.000931	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1B—stomach cancer	0.000173	0.000915	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6—stomach cancer	0.000168	0.000891	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCND1—stomach cancer	0.000165	0.000873	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JUN—stomach cancer	0.000165	0.000871	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP9—stomach cancer	0.00016	0.000847	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1A—stomach cancer	0.00016	0.000844	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAPK8—stomach cancer	0.000156	0.000824	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFA—stomach cancer	0.000144	0.000761	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STAT3—stomach cancer	0.000142	0.000753	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAPK3—stomach cancer	0.000136	0.00072	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MYC—stomach cancer	0.000132	0.0007	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAPK1—stomach cancer	0.000129	0.000685	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGFR—stomach cancer	0.000129	0.000685	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KRAS—stomach cancer	0.000122	0.000647	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CA—stomach cancer	0.000112	0.000594	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TP53—stomach cancer	0.000109	0.000575	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HRAS—stomach cancer	0.000104	0.00055	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6—stomach cancer	9.95e-05	0.000526	CbGpPWpGaD
